158 related articles for article (PubMed ID: 20593240)
1. Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP.
Almendingen K; Larsen LN; Fausa O; Bratlie J; Høstmark AT; Aabakken L
Fam Cancer; 2010 Dec; 9(4):571-80. PubMed ID: 20593240
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
[TBL] [Abstract][Full Text] [Related]
4. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Brosens LA; Iacobuzio-Donahue CA; Keller JJ; Hustinx SR; Carvalho R; Morsink FH; Hylind LM; Offerhaus GJ; Giardiello FM; Goggins M
Clin Cancer Res; 2005 Jun; 11(11):4090-6. PubMed ID: 15930344
[TBL] [Abstract][Full Text] [Related]
5. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis.
Reding T; Bimmler D; Perren A; Sun LK; Fortunato F; Storni F; Graf R
Gut; 2006 Aug; 55(8):1165-73. PubMed ID: 16322109
[TBL] [Abstract][Full Text] [Related]
6. Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls.
van Heumen BW; Roelofs HM; te Morsche RH; Nagengast FM; Peters WH
Orphanet J Rare Dis; 2013 Nov; 8():181. PubMed ID: 24245549
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 induction after oral surgery does not entirely account for analgesia after selective blockade of cyclooxygenase 2 in the preoperative period.
Fornai M; Colucci R; Graziani F; Cei S; Antonioli L; Tonelli M; Vassalle C; Blandizzi C; Gabriele M; Del Tacca M
Anesthesiology; 2006 Jan; 104(1):152-7. PubMed ID: 16394701
[TBL] [Abstract][Full Text] [Related]
9. Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial.
Iwama T; Akasu T; Utsunomiya J; Muto T
Int J Clin Oncol; 2006 Apr; 11(2):133-9. PubMed ID: 16622748
[TBL] [Abstract][Full Text] [Related]
10. Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression.
Liu NN; Sun YZ; Zhao N; Chen L
Clin Exp Ophthalmol; 2015 Jul; 43(5):458-65. PubMed ID: 25472856
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
14. Combining paracetamol with a selective cyclooxygenase-2 inhibitor for acute pain relief after third molar surgery: a randomized, double-blind, placebo-controlled study.
Haglund B; von Bültzingslöwen I
Eur J Oral Sci; 2006 Aug; 114(4):293-301. PubMed ID: 16911100
[TBL] [Abstract][Full Text] [Related]
15. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.
Fenwick SW; Toogood GJ; Lodge JP; Hull MA
Gastroenterology; 2003 Sep; 125(3):716-29. PubMed ID: 12949718
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
[TBL] [Abstract][Full Text] [Related]
17. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
[TBL] [Abstract][Full Text] [Related]
18. Altered monocyte cyclo-oxygenase response in non-obese diabetic mice.
Beyan H; Buckley LR; Bustin SA; Yousaf N; Pozzilli P; Leslie RD
Clin Exp Immunol; 2009 Feb; 155(2):304-10. PubMed ID: 19040607
[TBL] [Abstract][Full Text] [Related]
19. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial.
Hefler LA; Grimm C; Speiser P; Sliutz G; Reinthaller A
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):251-4. PubMed ID: 16188370
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
